$7.66 Million in Sales Expected for OptimizeRx Co. (NASDAQ:OPRX) This Quarter

Wall Street brokerages forecast that OptimizeRx Co. (NASDAQ:OPRX) will announce $7.66 million in sales for the current quarter, Zacks reports. Three analysts have made estimates for OptimizeRx’s earnings, with estimates ranging from $7.40 million to $7.93 million. OptimizeRx posted sales of $6.58 million in the same quarter last year, which suggests a positive year over year growth rate of 16.4%. The firm is scheduled to announce its next quarterly earnings report after the market closes on Thursday, February 27th.

On average, analysts expect that OptimizeRx will report full year sales of $24.88 million for the current financial year, with estimates ranging from $24.62 million to $25.15 million. For the next fiscal year, analysts forecast that the firm will report sales of $33.87 million, with estimates ranging from $33.23 million to $34.47 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that follow OptimizeRx.

OPRX has been the topic of several research analyst reports. ValuEngine upgraded shares of OptimizeRx from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 4th. TheStreet cut shares of OptimizeRx from a “c” rating to a “d+” rating in a research report on Wednesday, November 20th. Zacks Investment Research cut shares of OptimizeRx from a “hold” rating to a “sell” rating in a research report on Tuesday, November 5th. B. Riley lowered their price objective on shares of OptimizeRx from $21.00 to $20.00 and set a “buy” rating on the stock in a research report on Monday, December 30th. Finally, William Blair initiated coverage on shares of OptimizeRx in a research report on Friday, January 3rd. They set an “outperform” rating on the stock. One equities research analyst has rated the stock with a sell rating, two have given a buy rating and one has issued a strong buy rating to the company. OptimizeRx presently has a consensus rating of “Buy” and a consensus target price of $18.00.

Several institutional investors have recently bought and sold shares of OPRX. Citigroup Inc. grew its holdings in shares of OptimizeRx by 304.2% during the 4th quarter. Citigroup Inc. now owns 2,765 shares of the company’s stock valued at $28,000 after acquiring an additional 2,081 shares in the last quarter. Rhumbline Advisers purchased a new position in shares of OptimizeRx during the 4th quarter valued at $108,000. Barclays PLC grew its holdings in shares of OptimizeRx by 34.7% during the 3rd quarter. Barclays PLC now owns 10,403 shares of the company’s stock valued at $151,000 after acquiring an additional 2,678 shares in the last quarter. UBS Group AG grew its holdings in shares of OptimizeRx by 34.9% during the 4th quarter. UBS Group AG now owns 17,000 shares of the company’s stock valued at $175,000 after acquiring an additional 4,397 shares in the last quarter. Finally, Atlantic Trust LLC grew its holdings in shares of OptimizeRx by 266.0% during the 4th quarter. Atlantic Trust LLC now owns 28,530 shares of the company’s stock valued at $293,000 after acquiring an additional 20,735 shares in the last quarter. Institutional investors and hedge funds own 58.93% of the company’s stock.

NASDAQ OPRX traded up $0.31 on Friday, hitting $11.29. 119,800 shares of the stock were exchanged, compared to its average volume of 67,139. OptimizeRx has a 52-week low of $8.63 and a 52-week high of $17.24. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.00 and a quick ratio of 7.00. The company has a market capitalization of $155.59 million, a price-to-earnings ratio of -125.44 and a beta of 0.31. The company’s 50-day moving average price is $10.64 and its two-hundred day moving average price is $12.21.

OptimizeRx Company Profile

OptimizeRx Corporation provides digital health messaging services for pharmaceutical companies to communicate with healthcare providers. The company's cloud-based solutions support patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and critical clinical information; and network consists of electronic health records platforms, which provide the ambulatory patient market with access to their workflow at the point-of-care.

Featured Article: How do investors use RSI to grade stocks?

Get a free copy of the Zacks research report on OptimizeRx (OPRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.